Extending the Use of Cerezyme for Type 3


Gauchers News Contents


Genzyme Therapeutics announced in June 2003 that the European Committee for Proprietary Medicinal Products (CPMP) has issued a positive opinion on expanding the indication for Cerezyme to include Type 3 Gauchers disease. Genzyme hopes to receive formal approval of the label expansion by the European Commission later this year.


'By broadening the licence in the European Union to cover patients with Type 3, this should help ensure continued access to Cerezyme by patients currently on therapy and to assist patients who have experienced difficulties in obtaining funding for a drug that was not specifically licensed for Type 3 Gauchers disease,' says Julie Kelly, Senior Sales Director of Genzyme Therapeutics UK . 'Genzyme intends to pursue a similar licence change in other countries. n


Gauchers News Contents

Source: Gauchers News October 2003.
© Copyright Gauchers Association Ltd 2003.